Doctor's Death After Getting the Covid Vaccine Is Investigated
A Florida physician developed an unusual blood disorder shortly after he received the Pfizer vaccine. It is not yet known if the shot is linked to the illness. (Source: NYT Health)
Source: NYT Health - January 12, 2021 Category: Consumer Health News Authors: Denise Grady and Patricia Mazzei Tags: your-feed-healthcare Vaccination and Immunization Coronavirus (2019-nCoV) Coronavirus Risks and Safety Concerns Deaths (Fatalities) Centers for Disease Control and Prevention Hemorrhagic Stroke immune thrombocytopenia Pfizer Inc Michael, Source Type: news

Doctor's Death After Getting the Covid-19 Vaccine Is Investigated
A Florida physician developed an unusual blood disorder shortly after he received the Pfizer vaccine. It is not yet known if the shot is linked to the illness. (Source: NYT Health)
Source: NYT Health - January 12, 2021 Category: Consumer Health News Authors: Denise Grady and Patricia Mazzei Tags: your-feed-healthcare Vaccination and Immunization Coronavirus (2019-nCoV) Coronavirus Risks and Safety Concerns Deaths (Fatalities) Centers for Disease Control and Prevention Hemorrhagic Stroke immune thrombocytopenia Pfizer Inc Michael, Source Type: news

Mycophenolate Shows Promise in Immune Thrombocytopenia Mycophenolate Shows Promise in Immune Thrombocytopenia
For patients with immune thrombocytopenia, adding mycophenolate to the standard of care (steroids) resulted in half as many treatment failures as steroids alone.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - December 14, 2020 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news

No Benefit From Tranexamic Acid Prophylaxis in Blood Cancers No Benefit From Tranexamic Acid Prophylaxis in Blood Cancers
Tranexamic acid prophylaxis did not reduce bleeding among patients with hematologic malignancies and severe thrombocytopenia and may do more harm than good.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with ...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
This study evaluated the ability of teclistamab to induce cytotoxicity and T-cell activation.About TeclistamabTeclistamab is an investigational bispecific antibody targeting both BCMA and CD3. BCMA, B-cell maturation antigen, is expressed at high levels on multiple myeloma cells.[3],[4],[5],[6],[7] Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce cytotoxicity of the targeted cells.5,6 Results from preclinical studies demonstrate that teclistamab kills myeloma cell lines and bone marrow-derived myeloma cells from heavily pretreated patients.6 Teclistamab is currently being evaluated in a...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. These data, presented as an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting (Abstract #177), continued to demonstrate a very hig...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized ...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Rigel and Medison Announce Health Canada Approval of TAVALISSE(R), an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
SOUTH SAN FRANCISCO, Calif. and PETACH TIKVA, Israel, Nov. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Medison Pharma (Medison) today announced that Health Canada has approved the new drug submissio... Biopharmaceuticals, Regulatory Rigel Pharmaceuticals, Medison Pharma, TAVALISSE, fostamatinib, thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 23, 2020 Category: Pharmaceuticals Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

CBD for LGS: Fewer Seizures, Increased Thrombocytopenia Risk CBD for LGS: Fewer Seizures, Increased Thrombocytopenia Risk
Two recent analyses of highly purified cannabidiol (CBD) used to reduce seizures in Lennox Gastaut syndrome (LGS) have shown it is effective in reducing seizures for 3 years.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 23, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
SEATTLE, Oct. 13, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has commenced a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration ( " FDA " or " the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - October 13, 2020 Category: Drugs & Pharmacology Source Type: news

What Are the Clinical Signs and Symptoms of Congenital Syphilis?
Discussion Syphilis is caused by the spirochete Treponema pallidum. It is a very old disease that despite understanding the organism and readily available treatment, still causes disease. Syphilis is transmitted sexually. According to the Centers for Disease Control, “[i]n 2018, a total of 35,063 cases of [Primary and Secondary] syphilis were reported in the United States, yielding a rate of 10.8 cases per 100,000 population …. This rate represents a 14.9% increase compared with 2017 (9.4 cases per 100,000 population), and a 71.4% increase compared with 2014 (6.3 cases per 100,000 population).” The incre...
Source: PediatricEducation.org - September 28, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Prognosis and rescue therapy for sepsis-related severe thrombocytopenia in critically ill patients
This study aims to explore the effect of severe thrombocytopenia on the prognosis of sepsis and the impact of a platelet-elevating drug (recombinant human thrombopoietin, rhTPO) for these sepsis patients. In this study, we included 249 sepsis patients diagnosed by sepsis 3.0, and these patients were classified into the three groups based on PC: normal (PC>= 100 x 109/L), mild-moderate thrombocytopenia (50 x 109/L (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 3, 2020 Category: Consumer Health News Source Type: news

Pediatric Radiological Case: Autoimmune Hepatitis Pediatric Radiological Case: Autoimmune Hepatitis
Review the imaging studies that led to the diagnosis of autoimmune hepatitis in this 11-year-old who presented with abnormal liver function tests, thrombocytopenia, and hypoalbuminemia.Applied Radiology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - July 28, 2020 Category: Radiology Tags: Radiology Journal Article Source Type: news

What Are Some Pediatric Oncological Emergencies?
Discussion Pediatric cancers in the US number about 12,000 per year. After injury, it is the second leading cause of death in children and adolescents. Cancer presentations vary widely, but often begin with non-specific symptoms that continue or progress depending on the location and tumor type. Patients can present with oncological emergencies especially if there are mechanical obstruction such as superior vena cava syndrome or cerebral herniation. More commonly are infections due to immunosuppression. Cancer treatment also causes its own myriad of problems that clinicians need to be aware of to diagnosis and treat, but a...
Source: PediatricEducation.org - July 20, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020
Basel, 13 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III VIALE-A study, evaluating Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. VIALE-A results were featured in the 25th European Hematology Association Virtual Congress Press Briefing on Saturda y 13 June 2020 at 08:30 CEST and will be presented at the congress during the Late-breaking Oral Session (abstract #LB2601) on Sunday 14 June 2020.“We are very pleased to p...
Source: Roche Media News - June 13, 2020 Category: Pharmaceuticals Source Type: news

Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020
Basel, 13 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III VIALE-A study, evaluating Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. VIALE-A results were featured in the 25th European Hematology Association Virtual Congress Press Briefing on Saturda y 13 June 2020 at 08:30 CEST and will be presented at the congress during the Late-breaking Oral Session (abstract #LB2601) on Sunday 14 June 2020.“We are very pleased to p...
Source: Roche Investor Update - June 13, 2020 Category: Pharmaceuticals Source Type: news

Janssen ’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-4528, an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy in the treatment of patients with relapsed or refractory multiple myeloma. Longer-term follow-up results from the Phase 1b portion of the study (n=29), to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #8505), show t...
Source: Johnson and Johnson - May 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Falling Splenectomy Rates in ITP Raise Questions Over Role Falling Splenectomy Rates in ITP Raise Questions Over Role
Splenectomy is being performed less and less often in immune thrombocytopenia due to the increased availability of medical therapies, resulting in a lower benefit of the procedure to patients, suggests UK data.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 11, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Clinical characteristics and predictors of outcomes of hopsitalised patients with Covid-19 in a London NHS trust: a retrospective cohort study
This report is one of the first studies to describe the characteristics and predictors of outcomes for hospitalised Covid-19 patients in the UK. It finds that older age, male sex and admission hypoxia, thrombocytopenia, renal failure, hypoalbuminaemia and raised bilirubin are associated with increased odds of death. Ethnic minority groups were over-represented in the cohort and, compared to white people, people of black ethnicity may be at increased odds of mortality. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 11, 2020 Category: Consumer Health News Source Type: news

Clinical characteristics and predictors of outcomes of hospitalised patients with Covid-19 in a London NHS trust: a retrospective cohort study, Imperial College London
This report is one of the first studies to describe the characteristics and predictors of outcomes for hospitalised Covid-19 patients in the United Kingdom. It finds that older age, male sex and admission hypoxia, thrombocytopenia, renal failure, hypoalbuminaemia and raised bilirubin are associated with increased odds of death. Minority ethnic groups were over-represented in the cohort and, compared to white people, people of black ethnicity may be at increased odds of mortality. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 6, 2020 Category: Consumer Health News Source Type: news

U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
HORSHAM, Pa., April 21, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy. The approval is based on positive results from the landmark Phase 3 E1912 study that was designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute, part of the National Institutes of Health. Today’s mi...
Source: Johnson and Johnson - April 22, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

A Case of Chronic Thrombocytopenia in a 17-Year-Old Female A Case of Chronic Thrombocytopenia in a 17-Year-Old Female
A case of gray platelet syndrome, a rare type of thrombocytopenia, is discussed. How is this disorder diagnosed and treated?Laboratory Medicine (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 12, 2020 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Amanita fuliginea poisoning with thrombocytopenia: a case series - Wang Q, Sun M, Lv H, Lu P, Ma C, Liu Y, Liu S, Tong H, Hu Z, Gao Y.
We present 3 cases of severe A. fuliginea poisoning associated with thrombocytopenia in China. Three patients consumed foraged A. fuliginea and developed nau... (Source: SafetyLit)
Source: SafetyLit - February 3, 2020 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news

Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma
This case of severe grade V thrombocytopenia caused by nivolumab highlights the need for clinicians to be aware of this potential adverse effect of immune-checkpoint inhibitors.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 14, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia
DURHAM, N.C., Jan. 13, 2020 -- (Healthcare Sales & Marketing Network) -- Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), has been granted Orphan Drug Designation1 (ODD) by the US Food and Drug Administr... Biopharmaceuticals, Oncology, FDA Dova Pharmaceuticals, avatrombopag, Chemotherapy-Induced, Thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 13, 2020 Category: Pharmaceuticals Source Type: news

Avatrombopag cost  effective for thrombocytopenia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 31, 2019 Category: Drugs & Pharmacology Source Type: news

Romiplostim for Chemotherapy-Induced Thrombocytopenia Romiplostim for Chemotherapy-Induced Thrombocytopenia
Does the thrombopoietin receptor agonist romiplostim expedite correction of thrombocytopenia caused by chemotherapy?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

How Does Gaucher Disease Present?
Discussion Gaucher disease (GD) was first described by Philippe Gaucher in 1882. It was the first lysosomal storage disease (LSD) described and is the comparison prototype for many variations and their treatment. There are about 50 LSD and more well-known ones include Fabry, Niemann-Pick and Pompe diseases. LSDs currently have more than 300 different enzymes or membrane proteins affected which cause central nervous system and visceral disease. Overall the frequency of LSDs in aggregate is 1:3000 – 7000 live births. GD has an estimated prevalence of 1:57,000 – 111,000. It is higher within the Ashkenazi Jewish po...
Source: PediatricEducation.org - December 9, 2019 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

EMA Panel Backs Fostamatinib (Tavalisse) for Chronic ITP EMA Panel Backs Fostamatinib (Tavalisse) for Chronic ITP
Fostamatinib, a spleen tyrosine kinase inhibitor, helps increase and maintain the platelet count and reduce bleeding risk in adults with chronic immune thrombocytopenia refractory to other treatments.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Med... Biopharmaceuticals, Regulatory Rigel Pharmaceuticals, fostamatinib, immune thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2019 Category: Pharmaceuticals Source Type: news

Nplate ® (romiplostim) now approved for earlier use in adults with immune thrombocytopenia
Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia (ITP), a rare, serious autoimmune disease characterized by low platelet counts. (Source: World Pharma News)
Source: World Pharma News - October 21, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Nplate(R) (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
32% of Patients Achieved Treatment-Free Remission for at Least Six Months in a Single-Arm Trial 93% of Patients Achieved a Platelet Response THOUSAND OAKS, Calif., Oct. 18, 2019 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ:AMGN) today ... Biopharmaceuticals, FDA Amgen, Nplate, romiplostim, Immune Thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 18, 2019 Category: Pharmaceuticals Source Type: news

Nplate (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
THOUSAND OAKS, Calif., Oct. 18, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 18, 2019 Category: Drugs & Pharmacology Source Type: news

Sobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology
The acquisition of Dova provides Sobi with Doptelet (avatrombopag), a differentiated on-market product in Chronic Immune Thrombocytopenia (ITP), a well established and growing market, for Chronic Liver Disease (CLD) and an ongoing phase 3 trial in Chemothe... Biopharmaceuticals, Mergers & Acquisitions Swedish Orphan Biovitrum, Sobi , Dova Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 30, 2019 Category: Pharmaceuticals Source Type: news

MPV, PDW, and PLT Count in ITP and Essential Thrombocytopenia MPV, PDW, and PLT Count in ITP and Essential Thrombocytopenia
This study analyzed and compared MPV and PDW values in immune thrombocytopenic purpura and essential thrombocythemia. How do they compare with values in healthy individuals?Laboratory Medicine (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 27, 2019 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

The Dengue Dance?
Discussion Dengue is an important arboviral infection that affects about 40% of the world population. It is found mainly in topical and subtropical areas of the world mainly in developing countries but it range is spreading including the United States. A review of common arboviruses can be found here. It is a flaviavirus with 4 distinct serotypes named DENV-1 through DENV-4 and is spread by A. aegypti a day biting mosquito. Infection with one serotype confers immunity to that serotype but not the others. It does offer some protection for cross-infection but this only lasts a few months. Incubation period is 3-14 days with ...
Source: PediatricEducation.org - July 29, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Whole-Blood Impedance Aggregometry for Diagnosing HIT Whole-Blood Impedance Aggregometry for Diagnosing HIT
Might whole-blood impedance aggregometry be a faster and simpler alternative to the gold-standard C-serotonin release assay for diagnosis of heparin-induced thrombocytopenia?American Journal of Clinical Pathology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 9, 2019 Category: Allergy & Immunology Tags: Pathology & Lab Medicine Journal Article Source Type: news

FDA Expands Indication for Platelet Booster Avatrombopag FDA Expands Indication for Platelet Booster Avatrombopag
Avatrombopag is now indicated for adults with thrombocytopenia and chronic immune thrombocytopenia; it is already approved for adults with thrombocytopenia and chronic liver disease.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 28, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Dova Pharmaceuticals Announces FDA Approval of Doptelet (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)
DURHAM, N.C., June 27, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 27, 2019 Category: Drugs & Pharmacology Source Type: news

Dova receives European marketing authorization
Dova Pharmaceuticals has received the nod from European regulators for the marketing of its drug, providing another avenue of potential for the company as it seeks to successfully land its commercialization effort. The Durham-based company (Nasdaq: DOVA) has received European Commission marketing authorization for Doptelet – its main drug for the treatment of severe thrombocytopenia in adult patients with chronic liver disease. The company's stock was up almost 10 percent Wednesday following… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 25, 2019 Category: Biotechnology Authors: Seth Thomas Gulledge Source Type: news

Dova receives European marketing authorization
Dova Pharmaceuticals has received the nod from European regulators for the marketing of its drug, providing another avenue of potential for the company as it seeks to successfully land its commercialization effort. The Durham-based company (Nasdaq: DOVA) has received European Commission marketing authorization for Doptelet – its main drug for the treatment of severe thrombocytopenia in adult patients with chronic liver disease. The company's stock was up almost 10 percent Wednesday following… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 25, 2019 Category: American Health Authors: Seth Thomas Gulledge Source Type: news

Young Girl Afraid Of IVs Invents ‘ Medi Teddy ’ To Disguise Them
(CNN) — A young girl from Connecticut turned her time spent in the hospital into a chance to help ease the fear of many other young patients. Ella Casano, now 12, was diagnosed with an autoimmune disease called Idiopathic Thrombocytopenia Purpura (ITP) when she was seven. “It’s when her body attacks and destroys its own platelets, so it puts her at higher risk for bleeding or injury, more than most people,” Meg Casano, Ella’s mother, told CNN. Due to ITP, Ella had to have IV infusions every six to eight weeks. As for many young children, and adults, this process scared her. “When I had m...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 14, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Source Type: news

An Assay for Screening of Heparin-Induced Thrombocytopenia An Assay for Screening of Heparin-Induced Thrombocytopenia
This study evaluated the usefulness of an alternative assay, the PIFA PLUSS P4, as a rapid screening test for the diagnosis of heparin-induced thrombocytopenia.Laboratory Medicine (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - May 13, 2019 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

What Clinical Symptoms Can An Infant with Polycythemia Have?
Discussion 1. What are indications for an exchange transfusion? 2. What are potential risks of partial exchange or exchange transfusion? 3. What are causes of anemia in different age groups? Related Cases Disease: Polycythemia | Blood and Blood Disorders Symptom/Presentation: Abnormal Laboratory Test | Respiratory Distress Specialty: Hematology | Neonatology Age: Premature Newborn To Learn More To view pediatric review articles on this topic from the past year check PubMed. Evidence-based medicine information on this topic can be found at SearchingPediatrics.com and the Cochrane Database of Systematic Reviews. Infor...
Source: PediatricEducation.org - April 29, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

ITP and B-cell Lymphoma Feature in Latest BSH Guidance ITP and B-cell Lymphoma Feature in Latest BSH Guidance
Recommendations on tackling osteoporosis in immune thrombocytopenia and mediastinal B-cell lymphoma management are the latest guidance by the British Society for Haematology in a prolific year.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 5, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news